Gateway Wealth Partners LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,433 shares of the company’s stock, valued at approximately $1,466,000.
Other institutional investors have also made changes to their positions in the company. Mascoma Wealth Management LLC bought a new stake in Astrazeneca in the first quarter valued at about $26,000. MV Capital Management Inc. bought a new position in Astrazeneca during the fourth quarter worth about $26,000. Reflection Asset Management bought a new position in Astrazeneca during the fourth quarter worth about $31,000. Raleigh Capital Management Inc. acquired a new stake in Astrazeneca during the first quarter valued at approximately $38,000. Finally, Avion Wealth boosted its holdings in Astrazeneca by 166.2% during the first quarter. Avion Wealth now owns 197 shares of the company’s stock valued at $38,000 after purchasing an additional 123 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca Trading Up 1.6%
Shares of AZN opened at $172.41 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The company has a market cap of $267.39 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 1.38 and a beta of 0.24. The stock has a fifty day moving average price of $180.02 and a two-hundred day moving average price of $187.95. Astrazeneca Plc has a 52-week low of $145.14 and a 52-week high of $212.71.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on AZN shares. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.
Check Out Our Latest Stock Report on Astrazeneca
Trending Headlines about Astrazeneca
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: Quarterly earnings beat expectations: AstraZeneca reported adjusted EPS of $2.63, above the $2.50 consensus estimate. Revenue rose 6.4% year over year to $15.38 billion, narrowly missing expectations, while oncology, cardiovascular and rare-disease medicines helped offset generic competition. AstraZeneca beats second-quarter profit expectations, holds outlook
- Positive Sentiment: Full-year outlook maintained: Management backed its 2026 forecasts, helping reassure investors that strength in key growth franchises can offset weaker sales, product exclusivity pressure and challenges in China. AstraZeneca earnings beat forecasts despite slight revenue miss
- Positive Sentiment: Some analysts remain constructive: Citi raised its price target to 17,800 pence, citing AstraZeneca’s potential drug pipeline and long-term revenue ambitions. AstraZeneca’s drug pipeline is splitting opinion among City analysts
- Neutral Sentiment: Pricing strategy is changing: An executive said AstraZeneca is adjusting pricing for new U.S. drug launches in response to the Trump administration’s most-favoured-nation policy. The changes could affect future pricing and margins, but the financial impact remains uncertain. AstraZeneca drug prices evolving in response to Trump policy
- Negative Sentiment: Pipeline setback adds pressure: Rare-disease drug Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation, renewing concerns about AstraZeneca’s longer-term growth pipeline. AstraZeneca’s rare disease drug misses main goal in late-stage trial
- Negative Sentiment: Analyst views are divided: Deutsche Bank reiterated a “sell” rating with an 11,500-pence valuation, highlighting uncertainty around pipeline execution and future growth. In addition, Pomerantz LLP announced an investigation into potential investor claims, which could create legal and reputational overhang. Pomerantz investor alert regarding AstraZeneca
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
